Enliven therapeutics to present at two upcoming investor conferences

Boulder, colo., may 29, 2024 (globe newswire) -- enliven therapeutics, inc. (enliven) (nasdaq: elvn), a clinical-stage precision oncology company focused on the discovery and development of next-generation small molecule kinase inhibitors, today announced that management will present at the following investor conferences in june:
ELVN Ratings Summary
ELVN Quant Ranking